K D Watenpaugh

发表

Programs for phasing by entropy maximization as implemented in Xtal3.2: a crystallographic software system.

J M Stewart, D M Collins, K D Watenpaugh, 1993, Acta crystallographica. Section D, Biological crystallography.

Structure-based design of nonpeptidic HIV protease inhibitors: the sulfonamide-substituted cyclooctylpyramones.

K D Watenpaugh, W. Howe, D. Anderson, 1997, Journal of medicinal chemistry.

Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class.

K D Watenpaugh, K. Watenpaugh, R. Tommasi, 1998, Journal of medicinal chemistry.

The crystal structure of a lysine 49 phospholipase A2 from the venom of the cottonmouth snake at 2.0-A resolution.

D. R. Holland, B C Finzel, K D Watenpaugh, 1994, The Journal of biological chemistry.

The Cyclin-dependent Kinases cdk2 and cdk5 Act by a Random, Anticooperative Kinetic Mechanism*

K D Watenpaugh, P. Clare, R. Poorman, 2001, The Journal of Biological Chemistry.

Structure-based design of nonpeptidic HIV protease inhibitors from a cyclooctylpyranone lead structure.

K D Watenpaugh, W. Howe, K. Watenpaugh, 1995, Journal of medicinal chemistry.

Comparison of the crystal structures of a flavodoxin in its three oxidation states at cryogenic temperatures.

K D Watenpaugh, A. Tulinsky, K. Watenpaugh, 1993, Journal of molecular biology.

Structure-based design of HIV protease inhibitors: 4-hydroxycoumarins and 4-hydroxy-2-pyrones as non-peptidic inhibitors.

K D Watenpaugh, W. Howe, K. Watenpaugh, 1994, Journal of medicinal chemistry.

Structure-based design of novel HIV protease inhibitors: carboxamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent nonpeptidic inhibitors.

K D Watenpaugh, W. Howe, A. Tomasselli, 1995, Journal of medicinal chemistry.

Macromolecular Crystallographic Information File.

P E Bourne, H M Berman, K D Watenpaugh, 1997, Methods in enzymology.

Structure-based design of HIV protease inhibitors: 5,6-dihydro-4-hydroxy-2-pyrones as effective, nonpeptidic inhibitors.

B C Finzel, K D Watenpaugh, W. Howe, 1996, Journal of medicinal chemistry.

A model of the complex between cyclin-dependent kinase 5 and the activation domain of neuronal Cdk5 activator.

K D Watenpaugh, K. Chou, R. Heinrikson, 1999, Biochemical and biophysical research communications.

Crystal structure of the catalytic subunit of Cdc25B required for G2/M phase transition of the cell cycle.

K D Watenpaugh, K. Watenpaugh, M R Deibel, 1999, Journal of molecular biology.